Back to search results

Tarlatamab for Advanced DLL3-Expressing Tumors

This study is testing a drug called tarlatamab for people with advanced tumors that have a specific marker called DLL3. Tarlatamab is already approved for a type of lung cancer, but it's considered investigational for other tumors in this study. The main goal is to see how well tarlatamab works (its "efficacy") by measuring if tumors shrink or disappear, and to understand any side effects. You might be able to join if you are 18 or older and have a confirmed advanced tumor that expresses DLL3, excluding small cell lung cancer or neuroendocrine prostate cancer. The study plans to enroll up to 29 participants.

Study design
This is a Phase 2, multi-center study that will enroll up to 29 participants. It's a "basket trial," meaning it includes different types of DLL3-expressing tumors.
What's involved
You will receive tarlatamab treatment until your disease gets worse, you experience unacceptable side effects, or you choose to stop. The treatment schedule involves specific doses on certain days within a 28-day cycle.
Compensation
Not stated in the trial record.
Follow-up
The main goal of the study, overall response rate, will be measured at 18 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06788938

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

Recruiting
PHASE2Ages 18+InterventionalTreatment
Jonsson Comprehensive Cancer Center
~29 participants
Updated 2026-05-18 on ClinicalTrials.gov
What's tested:Tarlatamab treatment

At a glance

Recruiting sites
5 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
1. Primary efficacy endpoint is overall response rate (ORR) as defined as complete response (CR) or partial response (PR) by RECIST 1.1 criteria. This is evaluated in the response evaluable set of patients.
Measured over 18 months

Conditions

DLL3-expressing Tumors
Advanced Tumors

Explore related trials

Digestive System Neuroendocrine NeoplasmExtrapulmonary Small Cell Neuroendocrine CarcinomaLarge Cell Neuroendocrine CarcinomaLung Small Cell CarcinomaNeuroendocrine CarcinomaSolid Neoplasm

Where it's being run

5 sites across 1 states
California5

Study leadership

  • Jonathan Goldman, MD · PRINCIPAL_INVESTIGATOR · UCLA / Jonsson Comprehensive Cancer Center

Who to contact

CRU Hotline
[email protected]
888-798-0719
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Low and intermediate grade neuroendocrine carcinoma (including carcinoid and atypical carcinoid)
Gastroenteropancreatic NEN
Large cell neuroendocrine carcinoma
SCLC transformed from previously-treated NSCLC
Extrapulmonary small cell carcinoma, with the exception of NEPC
Any other tumor type that meets staging and DLL3 positivity criteria 4. Positive DLL3 expression by immunohistochemistry on tumor biopsy.

Exclusion

Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
Adequately treated cervical carcinoma in situ without evidence of disease.
Adequately treated breast ductal carcinoma in situ without evidence of disease.
Prostatic intraepithelial neoplasia without evidence of prostate cancer.
Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ. 13. History of myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association, class II) within 6 months prior to first dose of study treatment. 14. History of arterial thrombosis (e.g., stroke or transient ischemic attack) within 6 months prior to first dose of study treatment. 15. Human immunodeficiency virus (HIV) infection.
Upon completion of antibiotics and resolution of symptoms, the participant may be considered eligible for the study from an infection standpoint.

What this trial measures

  • 1. Primary efficacy endpoint is overall response rate (ORR) as defined as complete response (CR) or partial response (PR) by RECIST 1.1 criteria. This is evaluated in the response evaluable set of patients.18 months